DISCOVERY
Primary objective: To evaluate the clinical efficacy and safety of different investigational therapeutics relative to the control arm in patients hospitalized with COVID-19. The primary endpoint is subject clinical status (on a 7-point ordinal scale) on Day 15.
Type of study: Interventional; Phase III, treatment
Treatment tested: Remdesivir, Lopinavir/Ritonavir, Interferon Beta 1-A, Hydroxychloroquine
Countries: European Union
Sample size: 3100
Study participants: Adults (≥18 year-old) hospitalized for COVID-19 with SpO2 ≤ 94% on room air OR acute respiratory failure requiring supplemental oxygen or ventilatory support.
Study status: Recruiting
Principal investigators
- Florence Ader: florence.ader@chu-lyon.fr
More information
- Study ID: NCT04315948
- Trial registry
Last updated: June 2020
Disclaimer
Note that study-related documents posted on the COVID-19 Clinical Research Coalition (COVID-19 CRC) website have been shared by coalition members for information. Some may have been approved by Ethics Review Boards and others may still be in draft form. Documents posted here may have been further amended before being used in the conduct of the respective trials they were designed for. It is recommended that users review these documents carefully and, if they plan to use them, adapt them appropriately for their intended use. The COVID-19 CRC and its members cannot accept any liability for any claim, loss or damages as a result of any reliance placed on, or use of, these documents.